Showing results (2121-2130 of 52,507) with videos related to
Sort By:
Pageof 5,251
Frontiers in Immunology|January 21, 2026
Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpuraHirofumi Kawamoto, Natsuko Sasaki, Yukimi Ueda, et al.Frontiers in Immunology|January 21, 2026
Robust neutralization of emerging JN.1 subvariants by the updated JN.1 vaccine: rationale for catch-up booster recommendations in high-risk individualsJu-Yeon Choi, Su-Hwan Kim, Soyoung Park, et al.Frontiers in Immunology|January 22, 2026
Cigarette smoke exposure triggers dendritic cell-derived exosome-mediated Th17 and Treg polarization through an autophagy- and necroptosis-associated SIRT1-dependent mechanism in vitroDongling Luo, Jifeng Liu, Leilei Ya, et al.Frontiers in Immunology|January 22, 2026
A novel liquid-liquid phase separation related gene signature including ARL6IP4 predicts prognosis and immune landscape in colorectal cancerTao Jiang, Yuqiu Li, Ning Ma, et al.Frontiers in Immunology|January 22, 2026
Identification of immune-related genes in diagnosing hypercholesterolemia with myocardial infarction through bioinformatics analysisWeibin Wu, Zheng Peng, Yi Yu, et al.Frontiers in Immunology|January 22, 2026
Ulcerative colitis model triggers gut α-Synuclein aggregation without brain involvement or neuronal loss in female ratsAna María Espinosa-Oliva, María Dolores Vázquez-Carretero, Rocío Ruiz, et al.Frontiers in Immunology|January 22, 2026
Revealing intra-group immunotherapy response heterogeneity in metastatic urothelial carcinoma through interpretable feature extraction and spectral clusteringYoshiyuki Nagumo, Xiucai Ye, Tianyi Shi, et al.Frontiers in Immunology|January 26, 2026
Strongyloides stercoralis coinfection impairs immune control of Mycobacterium tuberculosis in TB infected individualsAnuradha Rajamanickam, Bindu Dasan, Arul Nancy Pandiarajan, et al.Frontiers in Immunology|January 26, 2026
The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world studyZhanyong Ouyang, Linting Zhang, Feng Wang, et al.Frontiers in Immunology|January 26, 2026
Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translationBiswanath Majumder, Santanu DattaPageof 5,251